[{"id":"5fdf4cec-8c24-426c-b0fb-4a851eb51a26","acronym":"","url":"https://clinicaltrials.gov/study/NCT02098967","created_at":"2021-01-18T09:41:28.884Z","updated_at":"2024-07-02T16:37:10.664Z","phase":"Phase 1","brief_title":"A Study of the Safety and Pharmacokinetics of RO6839921, An MDM2 Antagonist, in Patients With Advanced Cancers, Including Acute Myeloid Leukemia.","source_id_and_acronym":"NCT02098967","lead_sponsor":"Hoffmann-La Roche","biomarkers":" GDF15","pipe":"","alterations":" ","tags":["GDF15"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RG7775"],"overall_status":"Completed","enrollment":" Enrollment 68","initiation":"Initiation: 04/21/2014","start_date":" 04/21/2014","primary_txt":" Primary completion: 05/07/2018","primary_completion_date":" 05/07/2018","study_txt":" Completion: 05/07/2018","study_completion_date":" 05/07/2018","last_update_posted":"2018-05-17"}]